Source: Genomeweb

Indivumed GmbH: Indivumed Launches Bioinformatics Platform, Expands Cancer Drug Discovery Efforts

The firm has revamped its business model to focus on AI-driven drug discovery and partnerships with pharma and academic cancer researchers.

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
100-250
Hartmut Juhl's photo - Founder & CEO of Indivumed GmbH

Founder & CEO

Hartmut Juhl

CEO Approval Rating

82/100

Read more